Skip to main content

Table 3 Studies comparing the prognostic value of synchronous vs. metachronous detection of CRCLM published in 2005–2018

From: Synchronous and metachronous liver metastases in patients with colorectal cancer—towards a clinically relevant definition

Reference

Year of publication

Cohort

Definition*

Synchronous/metachronous

OS

DFS

Mutsaerts et al. [16]

2005

Operated

2

43/59

S (p = 0.048)

NR

Leporrier et al. [17]

2006

All

3

250/108

NS (p = 0.498)

NR

Minagawa et al. [18]

2006

Operated

1

187/182

NS (p = 0.19)

NR

Taniai et al. [19]

2006

Operated

4

67/41

NS (p = 0.354)

NR

Shimizu et al. [20]

2007

Operated

3

70/94

NS (p = 0.738)

NR

Tsai et al. [21]

2007

Operated

1

97/58

NS (p = 0.150)

S (p = 0.004)

Wang et al. [22]

2007

Operated

3

514/409

NS (p = 0.312)

NR

Bockhorn et al. [23]

2008

Operated

4

101/101

NS (p = 0.78)

NS (p = 0.28)

Hamady et al. [24]

2008

Operated

4

138/46

NS (p = 0.6)

NR

Vigano et al. [25]

2008

Operated

1

55/66

S (p = 0.011)

NR

Konopke et al. [26]

2009

Operated

1

70/131

S (p = 0.030)

NR

Ng et al. [27]

2009

Operated

2

35/20

NS (p = 0.075)

NS (p = 0.43)

Xu et al. [28]

2009

Operated

3

379/290

NS (p > 0.05)

NR

Tonelli et al. [29]

2010

Operated

1

70/37

S (p = 0.018)

NR

Van der Pool et al. [30]

2010

Operated

1

105/167

NS (p = 0.6)

NS (p = 0.3)

Brouquet et al. [31]

2011

Operated

1

47/13

S (p = 0.003)

NR

Settmacher et al. [7]

2011

Operated

1

158/224

S (p = 0.033)

S (p = 0.003)

Swan et al. [32]

2011

Operated

4

577/625

NS (p = 0.530)

NR

Furukawa et al. [33]

2012

Unresectable

1

26/14

NS (p = 0.085)

NA

Vigano et al. [34]

2012

Operated

1

182/194

NS

NR

Dexiang et al. [35]

2012

All

3

1061/552

S (p < 0.001)

NR

Gur et al. [36]

2013

Operated

1

79/79

NS (p = 0.14)

S (p = 0.04)

Nanji et al. [37]

2013

Operated

1

125/195

S (p = 0.003)

NS (p = 0.092)

Ribeiro et al. [38]

2012

Operated

3

89/81

NS (p = 0.162)

NS (p = 0.214)

John et al. [39]

2013

Operated

4

257/174

NS (p = 0.253)

NR

Hackl et al. [3]

2014

All

2

1019/407

NS (p = 0.799)

NR

Kumar et al. [40]

2014

All

1

1054/542

S (p = 0.003)

NR

Kuo et al. [41]

2015

Operated

2

104/55

S (p = 0.001)

NR

Ali et al. [42]

2015

Operated

3

66/50

NS (p = 0.997)

NR

Kawamura et al. [43]

2016

Operated

1

34/38

S (p = 0.010

NS

Lemke et al. [44]

2016

Operated

3

68/84

S (p = NR)

NR

Miller et al. [45]

2017

Operated

3

181/46

NS (p = 0.58)

NS (p = 0.87)

Angelsen et al. [46]

2017

Operated

4

39/488

NS (p = 0.068)

NR

Bartolini et al. [47]

2018

Operated

1

39/31

NS (p = 0.085)

S (p = 0.0001)

Margonis et al. [48]

2018

Operated

3

266/583

S (p = 0.02)

NS (p = 0.58)

Marques et al. [49]

2018

Operated

3

95/55

NS (p = 0.505)

NS (p = 0.07)

Memeo et al. [50]

2018

Operated

4

753/1031

NS (p = NR)

NR

Quireze et al. [51]

2018

All

3

38/16

S (0.036) metachronous worse

NS (p = 0.629)

Suthananthan et al. [52]

2018

All

1

276/98

NS (p = 0.172)

NR

Strandberg et al. [53]

2018

Operated

1

146/138

S (p = 0.031)

NR

Zhao et al. [54]

2018

Operated

1

172/71

NS (p = 0.110)

NS (p = 0.088)

  1. *Definition: 1, Time of primary tumour diagnosis/operation; 2, 3 months after primary tumour diagnosis/operation; 3, 6 months after primary tumour diagnosis/operation; 4, 12 months after primary tumour diagnosis/operation. NA not applicable, NR not reported, S significant, NS non-significant, OS overall survival, DFS disease-free survival